COOThe Cooper Companies, Inc.
The Cooper Companies, Inc. (COO) sells medical devices and vision care products, including surgical instruments, orthopedic implants, and contact lenses. The next catalyst is Oct 6, 2026 — Insider Selling: Cerebras Sy, which will test the company’s ability to manage shareholder confidence amid internal capital flows.
- Revenue reached $4.23B in 2026, with a 5.1% YoY growth.
- Free cash flow (TTM) stands at $1.23B, supporting strong leverage and a debt-to-equity ratio of 0.30x.
- Net margin (TTM) is 9.6%, reflecting disciplined cost control and pricing power.
The schedule
- Thu29Oct
This earnings print will test the company's ability to deliver consistent results amid macroeconomic uncertainty. The outcome will also highlight the performance of its key product lines and any potential shifts in the product mix.
- Thu3Dec
This earnings print will test the company's ability to maintain margins and manage inventory mix amid macroeconomic headwinds. The outcome will also provide insight into the performance of its core ophthalmic products and any potential shifts in the product portfolio.
- Thu3Dec
This earnings print will test the company's ability to maintain margins and manage inventory mix amid macroeconomic headwinds. The outcome will also provide insight into the performance of its core ophthalmic products and any potential shifts in the product portfolio.
- Thu4Mar
- Tue14Sep
This event could signal a shift in sentiment among key stakeholders, potentially impacting short-term price action and investor confidence.
Past
- Tue6Oct
Insider selling could signal a shift in sentiment among key stakeholders, potentially impacting short-term price action and investor confidence.
- Thu5Mar
Actual outcome: Bear · $75.82 at outcome
Although CooperCompanies reported a Q1 earnings beat and raised its full-year guidance behind strong MiSight and MyDay growth, the stock plummeted as the results failed to satisfy the high growth expectations required by its elevated P/E multiple. Investors appeared to focus on underlying risks such as international revenue trends and potential tariff headwinds, driving the price significantly below the bear floor of $77.50 to $69.92 by the run date.
